Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association discusses pharmacists’ role in diabetes and CKD care from ASN Kidney Week 2026
|Videos|October 15, 2015
DEA Requirements for Handling Controlled Substances
James Schiffer, RPh, associate at Allegaert Berger & Vogel LLC, discusses some of the DEA's requirements for handling controlled substances.
Advertisement
James Schiffer, RPh, associate at Allegaert Berger & Vogel LLC, discusses some of the DEA's requirements for handling controlled substances.
This video was recorded at the National Community Pharmacists Association's (NCPA) 2015 Annual Convention.
Advertisement
Related to this article
Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.
Young adults who vaped daily but never smoked had lower flow-mediated dilation and peak oxygen uptake than peers who used neither product.
Pharmacists can reduce COVID-19 vaccine hesitancy through honest, nonjudgmental communication and by using every patient touchpoint as an opportunity to offer vaccination.
Expert Q&A: Geisinger Investigator Discusses Low Flu Vaccination Rates, ICU Findings in Older Adults
A study author explains how pharmacists can help close vaccination gaps in rural communities and what lower ICU admission rates among vaccinated older adults may mean.
From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
Kidney Week 2026 posters show low-density lipoprotein cholesterol (LDL-C) fell by half in patients receiving dialysis, and oral enlicitide needed no dose adjustment for renal impairment.
Walgreens adds virtual coverage navigation, Medicare GLP-1 Bridge support, and pharmacist follow-up calls as GLP-1 discontinuation remains high.
Advertisement
Advertisement
Trending on Pharmacy Times
1
COVID-19 ‘Is Not Done With Us’: Pharmacist Urges Continued Vaccination Ahead of Seasonal Peaks
2
Tarlatamab and Next-Generation Targeted Agents Headline ESMO 2026 Lung Cancer Data
3
PCSK9 Inhibition Lowers LDL-C in Patients With Kidney Disease
4
Ribociclib Survival Data Anchor a Sobering ESMO 2026 for Breast Cancer
5